Drug intelligence / Profile preview

ingitamig

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

ingitamig (CC-92328) is a tri-specific natural killer (NK) cell engager immunotherapy designed to stimulate NK cell-mediated cytotoxicity against cancer cells. It is being developed primarily for the treatment of relapsed and/or refractory multiple myeloma. The drug functions by engaging NK cells and directing them to target tumor-associated antigens, specifically B-cell maturation antigen (BCMA), leading to immunologic cytotoxicity. ingitamig is a recombinant fusion protein classified as an antineoplastic and immunotherapy agent. The originator of the drug is Dragonfly Therapeutics, with development led by Celgene Corporation (a subsidiary of Bristol Myers Squibb)

Other names: TriNKET

Targets

BCMA (B-cell maturation antigen)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on ingitamig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ingitamig.

Explore the full profile